Securities code: 688366 Securities abbreviation: Haohaishengke Announcement No.: 2025-016

Shanghai Haohai Biotechnology Co., Ltd

Announcement on the change of sponsor representatives for continuous supervision

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Shanghai Haohai Biotechnology Co., Ltd. (hereinafter referred to as the "Company") recently received the "Letter from UBS Securities Co., Ltd. on Changing the Sponsor Representative of the Initial Public Offering of Shanghai Haohai Biotechnology Co., Ltd." issued by UBS Securities Co., Ltd. (hereinafter referred to as "UBS Securities"). UBS Securities is the sponsor of the Company's 2019 initial public offering of A-shares (hereinafter referred to as the "Project"), and originally appointed Mr. Sun Lijun and Mr. Luo Yong as the sponsor representatives for the continuous supervision of the Project.

Recently, Mr. Luo Yong, one of the original sponsor representatives of the project, no longer served as the sponsor representative of the project due to work changes. In order to ensure the orderly progress of the continuous supervision work, UBS Securities appointed Mr. Gu Chengzong (see attached resume) to replace Mr. Luo Yong as the sponsor representative of the continuous supervision of the project to continue to perform relevant duties.

After this change, the sponsor representatives of this project are Mr. Sun Lijun and Mr. Gu Chengzong. The statutory continuous supervision period of this project will end on December 31, 2022, and UBS Securities will continue to carry out continuous supervision on matters related to the raised funds as the raised funds have not been used up.

This change does not affect UBS Securities' continuous supervision of the company, and the company's board of directors would like to express its heartfelt gratitude to Mr. Luo Yong for his contribution during his tenure as the company's sponsor representative.

The announcement is hereby made.

Board of Directors of Shanghai Haohai Biotechnology Co., Ltd

April 12, 2025

Annex:

Biography of Mr. Gu Chengzong

Gu Chengzong, male, sponsor representative, is currently the executive director of the global investment banking department of UBS Securities, with a master's degree in international trade and a bachelor's degree in economics from Shanghai Jiao Tong University, and is a third-level candidate for Certified Financial Analyst (CFA). Mr. Gu Chengzong has participated in the execution of domestic equity financing projects such as the 1.568 billion yuan A-share IPO of Mecca Xincai, the 1.844 billion yuan A-share IPO of Frontier Biotech, the 1.816 billion yuan A-share IPO of Spring Airlines, the 30 billion yuan non-public offering of domestic preferred shares of Shanghai Pudong Development Bank, the 29.8 billion yuan A-share non-public offering of Bank of Communications, the introduction of Nanjing Pharmaceutical and the strategic investors of Boots, and the 3.5 billion yuan A-share non-public offering of Spring Airlines. At the same time, he has also participated in bond financing projects and overseas equity financing projects of many enterprises.